Ishihara, Hiroki http://orcid.org/0000-0002-5146-656X
Nemoto, Yuki
Nakamura, Kazutaka
Tachibana, Hidekazu
Fukuda, Hironori
Yoshida, Kazuhiko
Kobayashi, Hirohito
Iizuka, Junpei
Shimmura, Hiroaki
Hashimoto, Yasunobu
Tanabe, Kazunari
Kondo, Tsunenori
Takagi, Toshio
Article History
Accepted: 1 April 2022
First Online: 23 April 2022
Declarations
:
: No external funding was used in the preparation of this article.
: Toshio Takagi received a speaker honorarium from Bristol-Myers Squibb and Ono Pharmaceutical. Tsunenori Kondo received a speaker honorarium from Pfizer, Novartis, Bristol-Myers Squibb, and Ono Pharmaceutical. Hiroki Ishihara, Yuki Nemoto, Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, and Kazunari Tanabe declare that they have no conflict of interest.
: The study protocol was approved by the Institutional Review Boards of Tokyo Women’s Medical University, Tokyo Women’s Medical University Medical Center East, Saiseikai Kawaguchi General Hospital, Saiseikai Kurihashi Hospital, and Jyoban Hospital (ID: 2020-0009). This study conforms to the ethical guidelines of the 1964 Declaration of Helsinki. The requirement for written informed consent was waived because of the retrospective observational nature of the study.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors contributed to the study conception and design, data collection, and data analysis. HI wrote the first draft of the manuscript, and all authors critically revised the manuscript for important intellectual content and approved the version to be published.